Artigo
Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
Carregando...
Notas
Data
Orientadores
Editores
Coorientadores
Membros de banca
Título da Revista
ISSN da Revista
Título de Volume
Editor
Springer Nature
Faculdade, Instituto ou Escola
Departamento
Programa de Pós-Graduação
Agência de fomento
Tipo de impacto
Áreas Temáticas da Extenção
Objetivos de Desenvolvimento Sustentável
Dados abertos
Resumo
Abstract
Background: Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement
therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for pre‑
dicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement.
Methods: This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID19 patients were included between March/2020 and September/2020. Variable selection was performed using
generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was
used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve
(AUC-ROC).
Results: The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3%
required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The
temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital
mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU
admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identifed using
GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The
MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (tem‑
poral AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall
performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online
risk calculator (https://www.mmcdscore.com/).
Conclusions: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying
hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.
Descrição
Área de concentração
Agência de desenvolvimento
Palavra chave
Marca
Objetivo
Procedência
Impacto da pesquisa
Resumen
ISBN
DOI
Citação
FIGUEIREDO, F. de A. et al. Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients. BMC Medicine, [S.I.], v. 20, 2022. DOI: https://doi.org/10.1186/s12916-022-02503-0.
Link externo
Avaliação
Revisão
Suplementado Por
Referenciado Por
Licença Creative Commons
Exceto quando indicado de outra forma, a licença deste item é descrita como acesso aberto

